ESH MM 2018 | Continuous vs. fixed duration therapy for multiple myeloma?

Jesús San Miguel

Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, discusses continuous and fixed duration therapy.

Share this video  
Similar topics
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
ESH MM 2018
Interview
5th October 2018
More from Jesús San Miguel
An update on immunotherapy for multiple myeloma in 2016
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Challenges in the treatment of multiple myeloma
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals